echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > After Xinlitai, the second biosimilar drug of 5 billion ``dulaglycotide'' starts clinical trial

    After Xinlitai, the second biosimilar drug of 5 billion ``dulaglycotide'' starts clinical trial

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 28th, the Insight database showed that Lepu Bio started the Phase I clinical trial of a biosimilar drug of dulaglutide for blood glucose control in patients with type 2 diabetes


    From: Insight database (http://db.


    GLP-1 receptor agonists are a new driving force for the rapid growth of the diabetes field in recent years, and the market size has approached half of that of insulin products


    Trulicity (Trulicity) is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and injected once a week.


    In addition to being approved for the treatment of type 2 diabetes, Trulicity was approved by the FDA in 2020 to reduce the risk of major adverse vascular events (MACE) in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or have multiple Cardiovascular risk factors


    In China, Eli Lilly's Duyida was approved for marketing in February 2019.


    From: Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.